Natriuretic Peptides and Echocardiography: When We Use Tests to Guide Testing

Impressive advances have been made in recent years in the treatment of chronic ambulatory heart failure (HF) with use of novel therapies for heart failure with reduced ejection fraction (HFrEF) estimated to add 6.3 additional life-years for a 55-year-old patient [1]. Identification of sodium glucose cotransporter 2 (SGLT2) inhibitors as a beneficial therapy for heart failure with preserved ejection fraction (HFpEF) is also likely to translate into improved clinical outcomes for future HFpEF patients [2].
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Editorial Source Type: research